News

Catalyst Awardees Win the Harrington Innovator-Scholar Award

September 01, 2021
Jennifer Chen and John Chorba, two UCSF Catalyst awardees, win the 2021 Harrington Innovator-Scholar Award for projects that also won the Catalyst Award. MORE

FDA Accepts Epygenix Therapeutics IND to Initiate a Clinical Trial

September 01, 2021
Epygenix Therapeutics, Inc. ("Epygenix"), a clinical-stage biopharmaceutical company focused on rare and intractable genetic epilepsy, announced today that the U.S.

eFFECTOR Debuts as Publicly Traded Next-Generation Oncology Company

August 27, 2021
eFFECTOR Therapeutics, a clinical-stage biotech company co-founded by University of California Professor of 
Urology Davide Ruggero and Cellular and Molecular Pharmacologist Kevan Shokat, today completed its business combination with Locust Walk Acquisition Corp. eFFECTOR Therapeutics expects its...

Encellin Closes $5.9M Seed Financing

August 12, 2021
Encellin, a personalized regenerative medicine biotech company, founded at the University of California San Francisco (UCSF), and developing novel cell-based approaches to deliver sustained therapies with a single implant, today announced the closing of a $5.9M Seed financing round. The round was...

UCSF Health Awards Returns for 3rd Year and Includes Life Sciences Awards

By Melissa Faukner on August 09, 2021
Preview Video Link for the Award Show can be viewed here

Sonoma Biotherapeutics Raises $265M

August 05, 2021
Biotech company Sonoma Biotherapeutics has raised $265 million in new funding, the company announced Wednesday. The funding will be used to advance its programs aiming to treat autoimmune and inflammatory conditions such as rheumatoid arthritis and type 1 diabetes.

Epygenix Therapeutics to Proceed With Trial for the Treatment of Dravet Syndrome

August 03, 2021
Epygenix Therapeutics, a clinical-stage biopharmaceutical company focused on rare and intractable genetic epilepsy that uses UCSF technology developed by Dr. Scott Baraban, is pleased to announce that the company's ARGUS trial with EPX-100 (Clemizole Hydrochloride) in patients with Dravet syndrome...

RxSight sets terms for $125 million IPO

July 27, 2021
RxSight, a commercial med-tech company based on UCSF post-cataract intraocular lens technology, announced terms for its IPO on Monday. The company plans to raise $125 million by offering 7.4 million shares at a price range of $16 to $18.  MORE

Erasca Announces Closing of Initial Public Offering

July 21, 2021
Erasca, Inc., a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the closing of its initial public offering of 21,562,500 shares of common stock, which includes...

Device taps brain waves to help paralyzed man communicate

July 14, 2021
University of California, San Francisco, neurosurgeon Dr. Edward Chang performs surgery at UCSF. In a medical first, researchers, led by Chang, harnessed the brain waves of a man paralyzed and unable to speak for 15 years - and turned what he intended to say into sentences on a computer screen. ...

Pages